Skip to content

Price / book at other companies

Pfizer logo
PfizerPFE
1.8×+0.2×
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
3.1×0.0×
CG Oncology logo
CG OncologyCGON
5.2×+2.6×
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
2.7×+2.0×
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
143.7×+142×
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
4.9×+3.8×

Other financials

Income statement

See full
Operating income-$39.6M-21.1%
Net income-$35.8M-19.1%
EPS (diluted)-$0.34+19.0%

Balance sheet

See full
Cash & equivalents$56.4M+14.3%
Total debt$3.3M+2.6%
Total equity$415.6M+89.1%
Total assets$436.8M+79.8%

Cash flow

See full
Operating cash flow-$32.4M+0.3%
CapEx$2.0K-99.5%
Free cash flow-$32.4M+1.5%

Valuation

See full
Market cap$976.17M+23.0%
Enterprise value$923.07M+23.5%

Returns & leverage

See full
Return on equity-42.6%-4.6pp
Debt / equity0.0×
Current ratio16.3×+4.3×

Where this comes from

Calculated from Oric Pharmaceuticals, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Oric Pharmaceuticals, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oric Pharmaceuticals, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oric Pharmaceuticals, Inc.'s price / book?
Oric Pharmaceuticals, Inc. (ORIC) reported price / book of 3.4× in Q1 2026.
How has Oric Pharmaceuticals, Inc.'s price / book changed year-over-year?
Oric Pharmaceuticals, Inc.'s price / book increased by 89.3% year-over-year, from 1.8× to 3.4×.
What is the long-term trend for Oric Pharmaceuticals, Inc.'s price / book?
Over 5 years (2020 to 2025), Oric Pharmaceuticals, Inc.'s price / book has grown at a -13.5% compound annual growth rate (CAGR), from 4.3× to 2.1×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.